Table 2.
Ongoing clinical trials evaluating the effects of nutraceuticals on vascular calcification.
| Trial Name | NCT | Intervention | Phase | Population | Enrolment | Primary Outcome |
|---|---|---|---|---|---|---|
| MAGiCal-CKD | NCT02542319 | Magnesium hydroxide vs. placebo | II-III | Predialysis CKD | 250 | Change in CAC score at 12 months |
| iPACK-HD | NCT01528800 | Vitamin K1 vs. placebo | II | Hemodialysis patients | 85 | Progression of CAC at 12 months |
| TReVasc-HDK | NCT02870829 | Menaquinone-7 vs. placebo | II | Hemodialysis patients | 178 | Difference in CAC score at 18 months |
| VitaK-CAC | NCT01002157 | Menaquinone-7 vs. placebo | - | CAC score between 50 and 400 | 180 | Change in CAC score at 12 and 24 months |
| AVADEC | NCT03243890 | Menaquinone-7 vs. placebo | - | AVC score above 300, without AVS | 389 | Progression of AVC at 2 years |
| BASIK2 | NCT02917525 | Vitamin K2 vs. placebo | II | Bicuspid AV and mild to moderate AVS | 44 | Progression of AV calcium at 6 months |
CKD, cronic kidney disease; CAC, Coronary Artery Calcification; AVC, aortic valve calcification; AVS, aortic valve stenosis.